This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (8)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Joan Stephenson, PhD

JAMA. 2000;284:1913-1914.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Toronto—For the first time, a vaccine against genital herpes infection appears to protect people against disease—but with limitations that may have implications for vaccines against sexually transmitted diseases (STDs).

Scientists reported here at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy that two large clinical trials found that a vaccine against herpes simplex virus 2 (HSV-2), the strain responsible for most cases of genital herpes, was highly effective compared with a placebo. But the vaccine showed effectiveness only in women, not men, and only in women who had not been previously infected with herpes simplex virus 1 (HSV-1), the strain responsible for most cases of oral herpes.

Previous attempts to develop a genital herpes vaccine had been unsuccessful, creating "a very negative attitude" about the likelihood of developing an effective vaccine, noted Spotswood Spruance, MD, of the University of Utah School of Medicine, who reported . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Protective Role of Locally Administered Immunostimulatory CpG Oligodeoxynucleotide in a Mouse Model of Genital Herpes Infection
Harandi et al.
J. Virol. 2002;77:953-962.
ABSTRACT | FULL TEXT  

Hormonal markers of susceptibility to sexually transmitted infections: are we taking them seriously?
Brabin
BMJ 2001;323:394-395.
FULL TEXT